Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts Details-
Title Grant Type Focus Area Country Application Due Date Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology Brazil, Chile, India, Italy, South Africa, Spain, United Kingdom Guideline Concordant Care and New Data for Patients with MIBC through la/mUCEducation Oncology USA Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast CancerRelease Date:Research Oncology Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, USA, United Kingdom Quality Improvement Interventions to Enhance the Care of Patients Infected by MBL-CRE or S. maltophiliaRelease Date:Quality Improvement Inflammation & Immunology Australia, Chile, India, Italy, Spain, United Kingdom Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease RegistryRelease Date:Research Inflammation & Immunology Germany Real-World Evidence on Clinical Outcomes with ATM-AVI in Adult Patients with Stenotrophomonas maltophilia InfectionsRelease Date:Research Inflammation & Immunology China Real-World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI) in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Tissue Penetration and Correlation with Clinical Outcomes of ATM-AVI in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Advancing Multidisciplinary Care in HemophiliaRelease Date:Quality Improvement Rare Disease China BCMA BsAb Educational Initiatives in 2L+ Relapsed/Refractory Multiple MyelomaRelease Date:Education Oncology USA -
Title Grant Type Focus Area Country Application Due Date Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA Capacity Building for Clinical Trials in Sickle Cell Disease (SCD) - Education for Healthcare ProfessionalsRelease Date:Education Rare Disease USA Prostate Cancer: Best Practices for Combining Targeted Therapies in mPCRelease Date:Education Oncology USA Transthyretin Cardiac Amyloidosis FellowshipRelease Date:Research Rare Disease USA Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology Spain Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA